Search results
Results from the WOW.Com Content Network
One of the E. coli asparaginases marketed under the brand name Elspar for the treatment of acute lymphoblastic leukemia [32] is also used in some mast cell tumor protocols. [ 33 ] In July 2006, the US Food and Drug Administration (FDA) granted approval to pegaspargase for the first-line treatment of people with acute lymphoblastic leukemia as a ...
The bacteria, E. coli, is commonly found in the human gut. Most strains of E. coli are harmless; however, if the bacterium gets into the bloodstream due to a weakened immune system it can cause ...
Efforts to induce this phenomenon have used cancer vaccines (derived from cancer cells or selected cancer antigens), or direct treatment with immune-stimulating factors on skin cancers. [53] Some oncolytic viruses are very immunogenic and may by infection of the tumour, elicit an anti-tumor immune response, especially viruses delivering ...
E. coli is a chemoheterotroph whose chemically defined medium must include a source of carbon and energy. [16] E. coli is the most widely studied prokaryotic model organism, and an important species in the fields of biotechnology and microbiology, where it has served as the host organism for the majority of work with recombinant DNA. Under ...
Some E. coli strains contain a polyketide synthase genomic island (pks), which encodes a multi-enzymatic machinery that produces colibactin, a substance that damages DNA. About 20% of humans are colonized with E. coli that harbor the pks island. [42] Colibactin can cause cellular senescence [43] or cancer by damaging DNA. [44]
While many Escherichia are commensal members of the gut microbiota, certain strains of some species, most notably the pathogenic serotypes of E. coli, are human pathogens, [7] and are the most common cause of urinary tract infections, [8] significant sources of gastrointestinal disease, ranging from simple diarrhea to dysentery-like conditions, [3] as well as a wide range of other pathogenic ...
The first example of this occurred in 1978 when Herbert Boyer, working at a University of California laboratory, took a version of the human insulin gene and inserted into the bacterium Escherichia coli to produce synthetic "human" insulin. Four years later, it was approved by the U.S. Food and Drug Administration.
Chemical structure of lipid A as found in E. coli [1]. Lipid A is a lipid component of an endotoxin held responsible for the toxicity of gram-negative bacteria.It is the innermost of the three regions of the lipopolysaccharide (LPS), also called endotoxin molecule, and its hydrophobic nature allows it to anchor the LPS to the outer membrane. [2]